Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Urologie (Heidelberg, Germany)|December 21, 2023
[First clinical and oncological experiences with triplet therapy for high-volume metastatic hormone-sensitive prostate cancer]Mike Wenzel, Benedikt Hoeh, Jan Kasparek, et al.
Medicina (Kaunas, Lithuania)|January 23, 2024
Cardiovascular Disease and Chronic Pulmonary Disease Increase the Risk of Short-Term Major Postoperative Complications after Robotic-Assisted Radical ProstatectomyCarolin Siech, Antonia Gruber, Mike Wenzel, et al.
Lower Urinary Tract Symptoms|April 23, 2026
Rates and Predictors of Persistent LUTS Medication Use After Laser Enucleation of the ProstateMaximilian Filzmayer, Miriam I Traumann, Clara Humke, et al.
Frontiers in Oncology|February 19, 2025
The association between the interval from biopsy to radical prostatectomy and biochemical recurrence in patients with intermediate- and high-risk prostate cancerCarolin Siech, Mike Wenzel, Georgina Knoblich, et al.
World Journal of Urology|December 28, 2024
Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancerMike Wenzel, Benedikt Hoeh, Clara Humke, et al.
European Urology Oncology|September 1, 2024
Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center AnalysisMike Wenzel, Cristiana Cano Garcia, Clara Humke, et al.
Urologic Oncology|July 11, 2026
Impact of number of bone metastases on cancer control outcomes in mHSPC, independent of the axial-skeleton CHAARTED definitionMike Wenzel, Lena Theissen, Carolin Siech, et al.
European Urology Focus|July 13, 2019
Performance of Combined Magnetic Resonance Imaging/Ultrasound Fusion-guided and Systematic Biopsy of the Prostate in Biopsy-naïve Patients and Patients with Prior BiopsiesFelix Preisser, Lena Theissen, Mike Wenzel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 13, 2025
Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapyMike Wenzel, Benedikt Hoeh, Carolin Siech, et al.
The Prostate|July 19, 2023
Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapyMike Wenzel, Cristina C Garcia, Benedikt Hoeh, et al.
Pageof 6